The results indicated that, in a highly heterogeneous set of 35 studies that compared endometrioid, serous, clear cells carcinoma and carcinosarcoma, the overall rate of WT1 expression was 25% (95% CI = 0.20–0.30; Q = 120.4; I2 = 71.7), with p < 0.05. This evidence concerns the gene WT1 and clear cell adenocarcinoma.